Search results
13 paź 2022 · Welcome to the British Journal of Cancer. The BJC is devoted to publishing cutting edge discovery, translational and clinical cancer research across the broad spectrum of oncology....
- Research articles
Read the latest Research articles from British Journal of...
- Reviews & Analysis
Read the Reviews & Analysis articles from British Journal of...
- News & Comment
Read the latest News & Comment articles from British Journal...
- Current issue
British Journal of Cancer (Br J Cancer) ISSN 1532-1827...
- Collections
Emerging Leaders - British Journal of Cancer BJC ’s Emerging...
- Journal Information
The British Journal of Cancer (BJC) is one of the most cited...
- Open access publishing
British Journal of Cancer are published OA under a CC BY...
- About the Editors
Jeff Evans is a Group Leader (Translational Cancer...
- Research articles
3 dni temu · Quiescent cancer cells induced by high-density cultivation reveals cholesterol-mediated survival and lung metastatic traits. Xingyang Liu; Qinjie Min; Qimin Zhan
14 wrz 2020 · Guide to Authors | British Journal of Cancer. On this page: Article types | Preparing your manuscript | Licence type | Open Access | Colour charges | Author tutorials | Journal cover...
17 godz. temu · Results . GdX exhibited low expression in the cancer tissues of BC patients and cell lines. MDA-MB-231 and MCF-7 cells overexpressing GdX displayed a notable reduction in proliferation and diminished migratory capabilities, accompanied by downregulated mRNA and protein expression of BCL-XL, Cyclin D1, and C-myc.
Introduction. Non–muscle invasive bladder cancer (NMIBC) represents ap-proximately 75% of all newly diagnosed cases of bladder can-cer, and high-risk NMIBC accounts for approximately one third of the disease burden [1].
British Journal of Cancer. Published by Springer Nature. Online ISSN: 1532-1827. ·. Print ISSN: 0007-0920. Articles. Not Available. Article. Full-text available. April 1956. ·. 13...
The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease control rate (DCR) at first scan, safety, and use of growth factor